Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
36.83 -0.59 (-1.58%) 12:07 ET [NASDAQ]
36.90 x 500 37.02 x 100
Realtime by (Cboe BZX)
36.90 x 500 37.02 x 100
Realtime 38.00 +0.58 (+1.55%) 09:28 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
36.81
Day High
38.90
Open 38.37
Previous Close 37.42 37.42
Volume 97,533 97,533
Avg Vol 450,378 450,378
Stochastic %K 50.93% 50.93%
Weighted Alpha -25.78 -25.78
5-Day Change +0.47 (+1.27%) +0.47 (+1.27%)
52-Week Range 29.24 - 53.27 29.24 - 53.27
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,423,506
  • Shares Outstanding, K 64,765
  • Annual Sales, $ 78,590 K
  • Annual Income, $ -146,960 K
  • EBIT $ -200 M
  • EBITDA $ -202 M
  • 60-Month Beta 2.18
  • Price/Sales 29.76
  • Price/Cash Flow N/A
  • Price/Book 2.73

Options Overview Details

View History
  • Implied Volatility 88.07% ( +0.80%)
  • Historical Volatility 61.26%
  • IV Percentile 99%
  • IV Rank 99.13%
  • IV High 88.38% on 06/03/24
  • IV Low 53.10% on 11/27/24
  • Put/Call Vol Ratio 10.00
  • Today's Volume 11
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 5,344
  • Open Int (30-Day) 5,207

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.76
  • Number of Estimates 13
  • High Estimate -0.08
  • Low Estimate -1.01
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -204.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.51 +10.70%
on 02/12/25
Period Open: 43.70
45.31 -18.13%
on 01/27/25
-6.60 (-15.11%)
since 01/21/25
3-Month
33.51 +10.70%
on 02/12/25
Period Open: 43.51
49.35 -24.84%
on 12/02/24
-6.41 (-14.74%)
since 11/21/24
52-Week
29.24 +26.86%
on 06/28/24
Period Open: 38.67
53.27 -30.36%
on 09/26/24
-1.57 (-4.07%)
since 02/21/24

Most Recent Stories

More News
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

KYMR : 36.83 (-1.58%)
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

KYMR : 36.83 (-1.58%)
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KYMR : 36.83 (-1.58%)
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

KYMR : 36.83 (-1.58%)
Insider Sale: Director at $KYMR (KYMR) Sells 2,500 Shares

Pamela Esposito, a director at $KYMR ($KYMR), sold 2,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares....

KYMR : 36.83 (-1.58%)
Kymera Therapeutics to Participate in Upcoming December Investor Conferences

KYMR : 36.83 (-1.58%)
Kymera Therapeutics to Participate in Upcoming November Investor Conferences

KYMR : 36.83 (-1.58%)
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KYMR : 36.83 (-1.58%)
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

KYMR : 36.83 (-1.58%)
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

KYMR : 36.83 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 39.43
2nd Resistance Point 38.74
1st Resistance Point 38.08
Last Price 36.83
1st Support Level 36.73
2nd Support Level 36.04
3rd Support Level 35.38

See More

52-Week High 53.27
Fibonacci 61.8% 44.09
Fibonacci 50% 41.26
Fibonacci 38.2% 38.42
Last Price 36.83
52-Week Low 29.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements